Your AI-Trained Oncology Knowledge Connection!
During a Targeted Oncology™ Case-Based Roundtable™ event, Paul A. DiSilvestro, MD, discussed with participants concerning the management of adverse events in a patient receiving single-agent immune checkpoint inhibitor for advanced mismatch-repair deficient endometrial cancer.
In separate, live virtual events, Robert J. Motzer, MD; and Moshe Ornstein, MD, MA, discussed the case of a patient with metastatic clear cell renal cell carcinoma (RCC) and options for therapy.
The role of immunotherapy continues to evolve for the treatment of patients with skin cancer, now with physicians able to choose between the use of single-agent vs dual immunotherapy treatments. In 2 separate Case-Based Roundtable events led by Alan Tan, MD, and Douglas B. Johnson, MD, MSCI, physicians considered these options for a patient with metastatic melanoma.
During a Targeted Oncology™ Community Case Forum event in collaboration with the Tennessee Oncology Practice Society, Jason Porter, MD, reviewed the CodeBreaK 100 and CodeBreaK 200 trials of sotorasib for patients with KRAS-mutant non–small cell lung cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, David M. O'Malley, MD, discussed with participants their experiences with using PARP inhibitors in patients with advanced ovarian cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Mohamed K. Mohamed, MD, PhD, and participants discussed cemiplimab plus chemotherapy and tremelimumab/durvalumab plus chemotherapy as regimens for a patient with metastatic squamous non–small cell lung cancer.
Wade T. Iams, MD, discusses molecular testing and multidisciplinary treatment for a patient with non–small cell lung cancer.
Hetty Carraway, MD, MBA, discusses treatment with tagraxofusp and allogeneic stem cell transplant for patients with blastic plasmacytoid dendritic cell neoplasm.
Hans Hammers, MD, PhD, discusses the case of a 59-year-old African American woman with clear cell renal cell carcinoma.
In an interview with Peers and Perspectives in Oncology, Tim Showalter, MD, MPH, discussed increasing patient quality of life by using artificial intelligence and precision medicine to inform cancer treatment decisions.
At a live, virtual event, Farrukh Awan, MD, provided commentary on the current treatment algorithm for patients with relapsed/refractory diffuse large B-cell lymphoma and where the use of the combination regimen tafasitamab and lenalidomide fits in.
